Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets
Deal Details and Company Background Hologic (NYSE: HOLX) is a Marlborough, MA–based medical technology firm focused on women’s health. Its products include mammography and breast biopsy systems, cervical cancer tests, surgical equipment (notably after its acquisition of Gynesonics), and lab diagnostics including molecular tests for Covid-19 bostonglobe.com. The Blackstone/TPG consortium will buy all outstanding Hologic shares for $76 cash plus a $3 CVR (contingent on hitting revenue goals in 2026–27 for the breast health business) marketscreener.com. This values the deal at $79 per share maximum and around $18.3 billion total enterprise value marketscreener.com. The purchase price represents a roughly 46%